Abstract
Regulation (EC) 1394/2007 of the European Parliament and the Council on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 allowed the use of non - authorized advanced therapy medicinal products under the certain circumstances. This socalled hospital exemption rule needs to be applied in the each Member State of the European Union individually and for this purpose Member States should provide national procedures and control measures. The aim of this article is to clear up the criteria for hospital exemption listed in Regulation (EC) 1394/2007 and to contrast the difference in implementing hospital exemption rule into national legal regimes on examples of the United Kingdom, Lithuania and Poland.
Keywords: Advanced therapy medicinal product, hospital exemption, regulation.
Current Stem Cell Research & Therapy
Title:Hospital Exemption for Advanced Therapy Medicinal Products: Issue in Application in the European Union Member States
Volume: 12 Issue: 1
Author(s): Tatjana Ivaskiene, Mykolas Mauricas and Justinas Ivaska
Affiliation:
Keywords: Advanced therapy medicinal product, hospital exemption, regulation.
Abstract: Regulation (EC) 1394/2007 of the European Parliament and the Council on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 allowed the use of non - authorized advanced therapy medicinal products under the certain circumstances. This socalled hospital exemption rule needs to be applied in the each Member State of the European Union individually and for this purpose Member States should provide national procedures and control measures. The aim of this article is to clear up the criteria for hospital exemption listed in Regulation (EC) 1394/2007 and to contrast the difference in implementing hospital exemption rule into national legal regimes on examples of the United Kingdom, Lithuania and Poland.
Export Options
About this article
Cite this article as:
Ivaskiene Tatjana, Mauricas Mykolas and Ivaska Justinas, Hospital Exemption for Advanced Therapy Medicinal Products: Issue in Application in the European Union Member States, Current Stem Cell Research & Therapy 2017; 12 (1) . https://dx.doi.org/10.2174/1574888X11666160714114854
DOI https://dx.doi.org/10.2174/1574888X11666160714114854 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuroprotection by NMDA Receptor Antagonists in a Variety of Neuropathologies
Current Drug Targets LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson’s Disease, Where Do We Stand?
Current Neuropharmacology Recent Developments in Deception Research
Current Psychiatry Reviews New Insights in Protein Kinase Conformational Dynamics
Current Topics in Medicinal Chemistry Psychosocial Factors and Central Sensitivity Syndromes
Current Rheumatology Reviews Therapeutic Targeting of TRP Channels - The TR(i)P to Pain Relief
Current Topics in Medicinal Chemistry Toward Inflatable Structures with Functional Phase Transitions: An Upto- Date Review with a View of Potentials
Recent Patents on Space Technology Nanofiber Scaffolds for Treatment of Spinal Cord Injury
Current Medicinal Chemistry Non-Demented Individuals with Alzheimer’s Disease Neuropathology: Resistance to Cognitive Decline May Reveal New Treatment Strategies
Current Pharmaceutical Design Reward-Seeking Behavior and Addiction: Cause or Cog?
Current Drug Abuse Reviews Central and Peripheral Pain Generators in Women with Chronic Pelvic Pain: Patient Centered Assessment and Treatment
Current Rheumatology Reviews Association of Oxidative Stress to the Genesis of Anxiety: Implications for Possible Therapeutic Interventions
Current Neuropharmacology Activin Receptor Signaling: A Potential Therapeutic Target for Osteoporosis
Current Molecular Pharmacology Patterns of Gray and White Matter Changes in Individuals at Risk for Alzheimer’s Disease
Current Alzheimer Research HIV-1: The Confounding Variables of Virus Neutralization
Current Drug Targets - Infectious Disorders Pharmacodynamics of Memantine: An Update
Current Neuropharmacology Modulation of Hepatic MRP3/ABCC3 by Xenobiotics and Pathophysiological Conditions: Role in Drug Pharmacokinetics
Current Medicinal Chemistry Autism: Pathophysiology and Promising Herbal Remedies
Current Pharmaceutical Design Malaria Vaccines: From the Laboratory to the Field
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Evaluating Intestinal Permeability by Measuring Plasma Endotoxin and Diamine Oxidase in Children with Acute Lymphoblastic Leukemia Treated with High-dose Methotrexate
Anti-Cancer Agents in Medicinal Chemistry